# Treg Modulation With CD28 and IL-6 Receptor Antagonists

> **NCT04066114** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (actual)

## Conditions studied

- Living-Donor Kidney Transplant
- Kidney Transplant Recipients

## Interventions

- **BIOLOGICAL:** lulizumab pegol
- **BIOLOGICAL:** antithymocyte globulin (rabbit)
- **DRUG:** methylprednisolone
- **BIOLOGICAL:** tocilizumab
- **DRUG:** Prednisone
- **DRUG:** everolimus
- **BIOLOGICAL:** belatacept
- **DRUG:** mycophenolate mofetil
- **DRUG:** mycophenolic acid

## Key facts

- **NCT ID:** NCT04066114
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-11
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-09-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-10-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04066114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04066114, "Treg Modulation With CD28 and IL-6 Receptor Antagonists". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04066114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*